Abstract
The use of agents capable of impairing RTK function is gaining prominence for their effectiveness against the tumorigenic program driven by oncogenic RTK activity in a wide range of cancer cells. Having this valuable resource in hand for molecularly targeted anticancer therapies, it is mandatory to understand how to use these agents properly for combined treatments in order to maximize clinical efficacy. The remarkable plasticity and adaptation of cancer cells should also be taken into account, since this leads to the acquisition of “resistance” during treatment. By revisiting mechanisms of drug resistance found in cancer cells and by intercalating new emerging concepts on RTK signaling coming from cancer genome studies, this review discusses strategies aimed to enhance the effectiveness of RTK blocking agents and overcome resistance to treatment.
Keywords: RTK-addiction, oncogenic RTKs, RTK anticancer agents, mechanism of drug action, resistance mechanisms, cell plasticity.
Current Medicinal Chemistry
Title:Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells
Volume: 21 Issue: 14
Author(s): Flavio Maina
Affiliation:
Keywords: RTK-addiction, oncogenic RTKs, RTK anticancer agents, mechanism of drug action, resistance mechanisms, cell plasticity.
Abstract: The use of agents capable of impairing RTK function is gaining prominence for their effectiveness against the tumorigenic program driven by oncogenic RTK activity in a wide range of cancer cells. Having this valuable resource in hand for molecularly targeted anticancer therapies, it is mandatory to understand how to use these agents properly for combined treatments in order to maximize clinical efficacy. The remarkable plasticity and adaptation of cancer cells should also be taken into account, since this leads to the acquisition of “resistance” during treatment. By revisiting mechanisms of drug resistance found in cancer cells and by intercalating new emerging concepts on RTK signaling coming from cancer genome studies, this review discusses strategies aimed to enhance the effectiveness of RTK blocking agents and overcome resistance to treatment.
Export Options
About this article
Cite this article as:
Maina Flavio, Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells, Current Medicinal Chemistry 2014; 21 (14) . https://dx.doi.org/10.2174/09298673113209990222
DOI https://dx.doi.org/10.2174/09298673113209990222 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Biological Activities of Organotin(IV) Complexes as Antitumoral and Antimicrobial Agents. A Review
Mini-Reviews in Medicinal Chemistry Angiogenesis and Hypoxia in Glioblastoma: A Focus on Cancer Stem Cells
CNS & Neurological Disorders - Drug Targets The Possible Role of Saponin in Type-II Diabetes- A Review
Current Diabetes Reviews Energetics of Quadruplex-Drug Recognition in Anticancer Therapy
Current Cancer Drug Targets Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions
Current Topics in Medicinal Chemistry P-glycoprotein Inhibition: The Past, the Present and the Future
Current Drug Metabolism Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer
Current Clinical Pharmacology Biological and Pharmacological Activities of Iridoids: Recent Developments
Mini-Reviews in Medicinal Chemistry Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design PAF Receptor and Tumor Growth
Current Drug Targets Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development
Recent Patents on Anti-Cancer Drug Discovery Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
Current Pharmaceutical Design Effects of Lipid Composition and Preparation Conditions on Physical-Chemical Properties, Technological Parameters and In Vitro Biological Activity of Gemcitabine-Loaded Liposomes
Current Drug Delivery The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews Natural Compounds and Drug Discovery: Can Cnidarian Venom Play a Role?
Central Nervous System Agents in Medicinal Chemistry Antitumor Effect of Butanoylated Heparin with Low Anticoagulant Activity on Lung Cancer Growth in Mice and Rats
Current Cancer Drug Targets COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice
Current Hypertension Reviews Engagement of Renin-Angiotensin System in Prostate Cancer
Current Cancer Drug Targets